Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.93 |
| ▸ | TSHR | P16473 | 2/20 | 0.93 |
| ▸ | MEN1 | O00255 | 1/20 | 0.93 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.93 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | MMP12 | P39900 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25541058 | 0.79 | RAB9A (0.66) | RAB9ATSHRMEN1CYP2C19KMT2A | |
| SCHEMBL19228585 | 0.79 | RAB9A (0.60) | RAB9ATSHRMEN1CYP2C19KMT2A | |
| SCHEMBL8917940 | 0.72 | MEN1 (0.53) | RAB9ATSHRMEN1CYP2C19KMT2A | |
| SCHEMBL16814072 | 0.72 | MEN1 (0.56) | RAB9ATSHRMEN1CYP2C19KMT2A | |
| SCHEMBL8918036 | 0.70 | CYP2C19 (0.50) | RAB9ATSHRMEN1CYP2C19KMT2A | |
| SCHEMBL23142238 | 0.70 | MEN1 (0.59) | RAB9ATSHRMEN1CYP2C19KMT2A | |
| SCHEMBL19031431 | 0.70 | MEN1 (0.54) | RAB9ATSHRMEN1CYP2C19KMT2A | |
| SCHEMBL19037364 | 0.70 | MEN1 (0.54) | RAB9ATSHRMEN1CYP2C19KMT2A | |
| SCHEMBL3048551 | 0.68 | HPGD (0.50) | RAB9ATSHRMEN1CYP2C19KMT2A | |
| SCHEMBL2776823 | 0.68 | TSHR (0.47) | RAB9ATSHRMEN1CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961258-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20200270273-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-27 | — | — | US | disclosed |
| WO-2017109724-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-29 | — | — | WO | disclosed |
| US-5691330-A | ANTIPSYCHOTIC AGENT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-11-25 | — | — | US | disclosed |
| US-5532240-A | ANTIPSYCHOTIC AGENTS AND ANTISEROTONIN AGENTS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
| EP-0596125-A1 | CONDENSED THIOPHENE COMPOUND AND PHARMACEUTICAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961258-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, BRAF | RAB9A 576/4885TSHR 661/4885MEN1 2734/4885 |
| US-20200270273-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, BRAF | RAB9A 576/4885TSHR 661/4885MEN1 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.